Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) / Sharman, J. P.; Munir, T.; Grosicki, S.; Roeker, L. E.; Burke, J. M.; Chen, C. I.; Grzasko, N.; Follows, G.; Matrai, Z.; Sanna, A.; Qiu, L.; Feng, R.; Hua, V. M.; Jurczak, W.; Ritgen, M.; Yi, S.; Bosch, F.; Coombs, C. C.; Bao, K.; Patel, V.; Liu, B.; Compte, L.; Guntur, A.; Wang, D. Y.; Hill, M.; Leow, C. C.; Ghia, P.; Barr, P. M.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 1527-7755. - 43:23(2025), p. 2658. [10.1200/JCO-25-01356]
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Ghia P.
;
2025-01-01
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
